Study ID | |
Title | |
Author | |
Country of study conduct | USA UK Canada Australia Other |
Study characteristics | |
Aim | |
Design | RCT Non-randomised experimental study Cohort study Cross-sectional study Case–control study Systematic review Qualitative study Prevalence study Case series Case report Diagnostic test accuracy study Clinical prediction rule Economic evaluation Text and opinion Other |
Start date | |
End date | |
Funding source | |
Conflict of interest | |
Participant characteristics | |
Population description | |
Inclusion criteria | |
Exclusion criteria | |
Sample size (n) | |
Birth weight (g) | |
Gestational age (week) | |
Postnatal age (week) | |
Underlying condition | |
Comorbidities | |
Concurrent medications | |
Intervention/exposure details | |
Paracetamol dosing regimen (mg/kg/dose) | |
Paracetamol duration (days) | |
Paracetamol route of administration | |
Control details | |
Pharmacotherapy | Sedative-analgesic Epidural NSAID Other |
Non-specified standard treatment | |
Outcomes | |
Primary outcomes | |
Long-term adverse effects | |
Neurodevelopmental adverse events | |
Atopic disorders | |
Reproductive disorders | |
Others | |
Secondary outcomes | |
Pharmacokinetic data | |
Pharmacodynamic data | |
Short-term adverse events | |
Increased hepatic transaminases | |
Gastrointestinal haemorrhage | |
Necrotising enterocolitis | |
Feeding intolerance |
IQ, intelligence quotient; NSAID, non-steroidal anti-inflammatory drug; RCT, randomised controlled trial.